At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 433 enrolled
Drug / intervention
Nebivolol +1 moredrug
Likely dose
Nebivolol 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of 5 mg or 20 mg Nebivolol Once Daily on Blood Pressure in Patients With Systolic Stage 2 Hypertension
In Brief
A Phase 4 clinical trial evaluating Nebivolol and Placebo for Hypertension. Completed, enrolled 433 participants across 36 sites.
Detailed Summary
The primary object of this study is to evaluate the efficacy and safety of 6 weeks of nebivolol monotherapy compared with placebo in patients with systolic stage 2 hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2010
Enrollment StartMar 2010
Primary CompletionDec 2010
Study CompletionJan 2011
TodayJul 2026
First PostedJan 27, 2010
Enrollment StartMar 1, 2010
Primary CompletionDec 1, 2010
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.4 years ago
Interventions
Nebivololdrug
5 mg, titrated to 20 mg, once daily oral administration
Placebodrug
5 mg or 20 mg once daily, oral administration